Article ; Online: Efficacy of Voclosporin in Proliferative Lupus Nephritis with High Levels of Proteinuria.
Clinical journal of the American Society of Nephrology : CJASN
2023 Volume 19, Issue 3, Page(s) 309–318
Abstract: Background: In a phase 3 study of adults with active lupus nephritis, addition of voclosporin to mycophenolate mofetil (MMF) and low-dose glucocorticoids led to significant improvements in the proportion of participants achieving complete and partial ... ...
| Abstract | Background: In a phase 3 study of adults with active lupus nephritis, addition of voclosporin to mycophenolate mofetil (MMF) and low-dose glucocorticoids led to significant improvements in the proportion of participants achieving complete and partial renal response as well as sustained reduction in proteinuria. This analysis examined the efficacy and safety of voclosporin in a subgroup of the phase 3 study with proliferative lupus nephritis and high levels of proteinuria. Methods: Participants were randomized to oral voclosporin (23.7 mg twice daily) or placebo for 12 months; all participants received MMF and low-dose glucocorticoids. This analysis includes participants with class III or IV (±class V) lupus nephritis and baseline urine protein-creatinine ratio (UPCR) ≥3 g/g. Efficacy end points included complete renal response (UPCR ≤0.5 g/g with stable eGFR, low-dose glucocorticoids, and no rescue medication), partial renal response (≥50% reduction from baseline UPCR), and UPCR over time. Safety outcomes were also assessed. Results: A total of 148 participants were in the voclosporin ( n =76) and control ( n =72) arms. At 12 months, 34% and 11% of participants in the voclosporin and control arms, respectively, achieved a complete renal response (odds ratio, 4.43; 95% confidence interval [CI], 1.78 to >9.99; P = 0.001). A partial renal response was achieved by 65% of the voclosporin arm and 51% of the control arm at 12 months (odds ratio, 1.60; 95% CI, 0.8 to 3.20; P = 0.18). More voclosporin- than control-treated participants achieved UPCR ≤0.5 g/g (51% versus 26%), and voclosporin-treated participants met this end point significantly earlier (hazard ratio, 2.07; 95% CI, 1.19 to 3.60; P = 0.01). The incidence of adverse events was similar between the arms; mean eGFR values remained stable and within normal range in both arms. Conclusions: Addition of voclosporin to MMF and low-dose glucocorticoids resulted in a significantly higher proportion of participants with proliferative lupus nephritis achieving complete and partial renal responses as well as earlier reductions in proteinuria, with no evidence of worsening kidney function. |
|---|---|
| MeSH term(s) | Adult ; Humans ; Lupus Nephritis/drug therapy ; Lupus Nephritis/complications ; Immunosuppressive Agents/adverse effects ; Cyclosporine/adverse effects ; Mycophenolic Acid/adverse effects ; Proteinuria/drug therapy ; Proteinuria/etiology ; Glucocorticoids/adverse effects ; Treatment Outcome |
| Chemical Substances | voclosporin (2PN063X6B1) ; Immunosuppressive Agents ; Cyclosporine (83HN0GTJ6D) ; Mycophenolic Acid (HU9DX48N0T) ; Glucocorticoids |
| Language | English |
| Publishing date | 2023-12-18 |
| Publishing country | United States |
| Document type | Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 2226665-3 |
| ISSN | 1555-905X ; 1555-9041 |
| ISSN (online) | 1555-905X |
| ISSN | 1555-9041 |
| DOI | 10.2215/CJN.0000000000000297 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6584: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.